Akinojin The CFTR protein forms a bronhciectasis channel that is critical to efficient mucus transport. A hypersensitivity response, known as allergic bronchopulmonary aspergillosis, may ensue, leading to a cycle of bronchial inflammation, mucoid impaction, and bronchial obstruction that results in bronchiectasis. In some people, inhalation of Aspergillus fumigatus provokes a brisk allergic response that is characterized by eosinophilia and a high level of IgE antibodies. Password must be at least 8 characters. A Woman with Recurrent Sinusitis, Cough, and Bronchiectasis NEJM Resident With the administration of these treatments at cystic fibrosis—specific treatment centers, median survival has increased from What are some of the causes of bronchiectasis? Back to Social Login.

Author:Dobei Arashizragore
Language:English (Spanish)
Genre:Health and Food
Published (Last):14 April 2009
PDF File Size:2.58 Mb
ePub File Size:15.8 Mb
Price:Free* [*Free Regsitration Required]

This article has been cited by other articles in PMC. As COPD is now becoming more common around the world, bronchiectasis is as well. Methods We review pertinent articles published before May that were retrieved by a selective PubMed search.

The few randomized trials of treatment for non-CF bronchiectasis that have been completed to date do not permit the formulation of any evidence-based recommendations. Many potential treatments are now under evaluation. Hypertonic saline is often used because of its demonstrated benefit in CF, even though no benefit has yet been shown for non-CF bronchiectasis. Phase II trials of inhaled mannitol have yielded promising results, leading to phase III trials that are now underway.

There may be a future role for inhaled antibiotics, particularly in patients colonized with Gram-negative pathogens. Inhaled tobramycin and colistin are well established in clinical practice, though not approved for non-CF bronchiectasis; clinical trials of aztreonam, ciprofloxacin, and gentamicin are ongoing.

Macrolides seem to bring an additional benefit, though the studies that documented this involved only small numbers of patients. Conclusion A national registry of patients with bronchiectasis should be established to help us gain better knowledge of its prognostic factors and treatment options. The term bronchiectasis describes a permanent dilation of the bronchi and bronchioles as a result of destruction of the muscles and elastic connective tissues.

The disorder mostly starts with a narrowing of the bronchial tree triggered by an infection, which may lead to destruction of the epithelium if it becomes chronic. The disruption of the mucociliary clearance results in retention of secretions and predestines the patient for further infections. In the past, bronchiectasis mostly had infectious causes, such as epidemics of pertussis, measles, and influenza.

The development of antibiotic treatments and vaccines has resulted in a continuous decrease in the number of cases of bronchiectasis with postinfectious causes in industrial countries. Currently, congenital causes of bronchiectasis are seen more observed than postinfectious causes. In Europe, bronchiectasis is common in patients with cystic fibrosis CF 1. However, in this review article we focus on patients with bronchiectasis in whom cystic fibrosis was excluded non-CF bronchiectasis.

This article aims to provide an overview over what is currently known from studies about the diagnostic evaluation and therapy of this heterogeneous pathology.

Method We conducted a selective literature search on PubMed. Relevant articles published before May were included in this review. Incidence and prevalence Because high-resolution computed tomography HRCT scanning is more commonly used nowadays, bronchiectasis is diagnosed earlier and at earlier stages. This has resulted in a seeming increase in the prevalence of bronchiectasis. The question of whether the increase in the numbers of cases is caused by the ageing population and the increase in chronic lung disorders will have to remain unanswered.

Very few data on prevalence are currently available. In New Zealand, the prevalence was reported to be 3. Different diagnostic methods clinical versus CT and a different selection of patients may be responsible for this discrepancy.

Pathophysiology and etiology Different mechanisms Table 1 lead to the development of bronchiectasis, but the pathophysiological end stage is similar. In the beginning, patients usually have damaged bronchial epithelium as a result of inflammation; the surrounding parenchyma is infiltrated by inflammatory cells Figure 1.

The destruction of the neighboring tissues results in dilation in the form of cylindrical, varicose, or cystic distensions with destruction of the surrounding structures. This will in turn lead to deficient mucociliary clearance.

The result is retention of secretions, which in turn attracts bacterial colonization with chronic inflammation 3. Furthermore, a thickening of the bronchial mucosa will ensue, which histologically shows notable metaplasias of the squamous epithelium, although an increased incidence in malignancies has not been observed. Table 1 Etiology of bronchiectasis modified from [ 7 ] Category.


A Woman with Recurrent Sinusitis, Cough, and Bronchiectasis

Kagahn This is the target of action of the drugs lumacaftor and tezacaftor. Many lung infections can result in the development of bronchiectasis, including those caused by Mycobacterium tuberculosis and Bordetella pertussis. The DH mutation is considered to be a partial-function mutation that results in diminished ion transport. A Woman with Recurrent Sinusitis, Cough, and Bronchiectasis This type of mutation is the target of the drug ivacaftor, which restores partial ion transport. Inthe qualifying mutations for the administration of ivacaftor were expanded to include DH.



Your doctor will listen to your lungs to check for any abnormal sounds or evidence of airway blockage. The main goal of treatment is to keep infections and bronchial secretions under control. Common methods of treating bronchiectasis include: methods for clearing the airways like breathing exercises and chest physiotherapy pulmonary rehabilitation antibiotics to prevent and treat infection — studies are currently being done on new formulations of inhaled antibiotics bronchodilators like albuterol Proventil and tiotropium Spiriva to open up airways medications to thin mucus oxygen therapy vaccinations to prevent respiratory infections You may need the help of chest physiotherapy. One form is a high-frequency chest wall oscillation vest to help clear your lungs of mucus. The vest gently compresses and releases your chest, creating the same effect as a cough. This dislodges mucus from the walls of the bronchial tubes. Another part of daily treatment involves draining of the bronchial secretions, aided by gravity.



Cystic fibrosis is a recessive genetic disease that is caused by mutations in both alleles of the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator CFTR. The CFTR protein forms a chloride channel that is critical to efficient mucus transport. Mutations in CFTR disrupt sodium absorption, chloride secretion, and water transport, leading to the development of viscous mucus that adheres to the airway and impairs bacterial clearance. There are close to recognized CFTR mutations, and each one confers a different degree of diminished chloride ion transport. Clinical Pearls Q: What are some of the causes of bronchiectasis? A: Bronchiectasis is characterized by irreversible damage of the airways that results in dilatation.


Bronchiectasis—Diagnosis and Treatment


Related Articles